News Center

Home page

Peak Report

News reports

Jianfeng Group Pro 2015-007 (Jianfeng Group Daily Related Party Transaction Announcement)

Release time:

2020-08-05

Securities Abbreviations: Jianfeng Group Securities Code: 600668 No.: Pro 2015-007

Bond Abbreviations: 13 Peak 01 Bond Code: 122227

Bond Abbreviations: 13 Peak 02 Bond Code: 122344

Zhejiang Jianfeng Group Co., Ltd.

Regular Related Party Transaction Announcement

The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and shall bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents .

Basic Information of 1. Daily Related Party Transactions

Review Procedures for Implementation of (I) Daily Related Party Transactions

Jinhua Pharmaceutical Co., Ltd. (hereinafter referred to as "Jinhua Pharmaceutical Company") purchases drugs from related party Tianjin Tianshili Pharmaceutical Marketing Group Co., Ltd. (hereinafter referred to as "Tianshili Marketing Group"). It is estimated that the purchase amount in 2015 will be between 0.5 and 5% of the company's audited net assets at the end of 2014 (no more than 103.0351 million yuan). Therefore, this related party transaction needs to be submitted to the board of directors for deliberation, but does not need to be submitted to the general meeting of shareholders for deliberation.

On April 17, 2015, the company held the second meeting of the ninth board of directors. All nine directors of the company attended the meeting in person. The related directors Mr. Jiang Xiaomeng and Mr. Du Zihong avoided voting on the proposal, which complied with the relevant provisions of the "Company Law" and the "Articles of Association", and the resolutions made were legal and effective. After deliberation and voting, the board of directors deliberated and passed the daily related party transaction proposal with 7 votes in favor, 0 votes against and 0 abstention.

The independent directors of the company reviewed the matter in advance and agreed to submit the proposal to the second meeting of the ninth board of directors of the company for deliberation. The independent directors of the company expressed their independent opinions on the adoption of the proposal by the board of directors, and believed that the formation of the resolution complied with the "Company Law", the company's "Articles of Association" and other relevant provisions, and did not harm the interests of small and medium shareholders.

Forecast and Implementation of (II)'s Last Daily Related Party Transaction

The Company issued a public announcement on April 15, 2014. It is estimated that the amount of drugs purchased by Jinhua Pharmaceutical Company from Tianshili Marketing Group in 2014 will be between 0.5 and 5% (between 8.685 million yuan and 86.8499 million yuan) of the Company's audited net assets at the end of 2013. The actual amount incurred in 2014 was 14.6314 million yuan, accounting for 2.13 percent of the amount of similar transactions, which did not exceed the expected range.

2. Related Party Introduction and Association Relationship

(I) the basic situation of related parties.

1. Jinhua Pharmaceutical Company: Established in January 1994, its domicile is located at 1180 Huancheng East Road, Jinhua City, its legal representative is Jin Xuecai, and its registered capital is 22 million yuan, of which: the company accounts for 10%, Zhejiang Jianfeng Pharmaceutical Co., Ltd., its holding subsidiary, accounts for 90%, and its main business is drug management. Wholesale and retail of prepackaged food; dangerous chemicals and medical devices; chemical reagents (except dangerous goods); glass and products; textiles, clothing and household daily necessities (except dangerous goods); fitness equipment supplies; computers, software and auxiliary equipment; wholesale and retail of teaching molds; exhibition services; medical information services; branches operate with valid certificates: purchase and processing of traditional Chinese medicine. The drug business license mainly includes: sales of proprietary Chinese medicines, Chinese medicinal materials, Chinese medicinal tablets, chemical preparations, chemical raw materials, antibiotics, biochemical drugs, biological products, narcotic drugs, psychotropic drugs, etc. The audited net profit for 2014 was 6.5056 million yuan, the net assets at the end of 2014 was 73.169 million yuan, and the liabilities were 237.9614 million yuan.

2, Tianshili Marketing Group: The company was established in 1999 February. The company's domicile is Tianshili Modern Chinese Medicine City, Xinyibai Avenue, Beichen Science and Technology Park, Tianjin, with its legal representative Yan Kaijing and registered capital of 25900 yuan, the business scope is the wholesale of Chinese herbal pieces, Chinese medicinal materials, Chinese patent medicines, chemical raw materials and their preparations, antibiotics, biochemical drugs, biological products, and diagnostic drugs; chemical raw materials ( except hazardous chemicals and precursor drugs ) , Wholesale and retail of cosmetics, daily chemical products, packaging materials and containers, plastic products, molds, and plastic raw materials; health food (hard capsules, soft capsules, granules, tablets, oral liquids, tea bags, health wine) wholesale and retail; disposable sterile syringes (needles), infusion sets (needles), corneal contact lenses and nursing solutions, medical polymer materials and products, physical therapy and rehabilitation equipment, medical hygiene materials and dressings, Chinese medicine equipment, general diagnosis equipment, Ward care equipment and appliances, household blood glucose meters and test strips, pregnancy diagnosis test strips, condoms wholesale; self-employed and agent of all kinds of goods and technology import and export business, but the state restricts the company to operate or prohibits the import and export of goods and technology, operating feed processing and "three to one supplement " business, operating trade and re-export trade, pre-packaged food wholesale and retail. The net profit attributable to the parent company in 2014 was 16,080.14 yuan, The net assets attributable to the parent company at the end of 2014 were 9,234.05 yuan, and the liabilities were 482,239.84 yuan.

The relationship between the (II) and the listed company

Because Tianshili Marketing Group is the holding subsidiary of Tianshili Pharmaceutical Group Co., Ltd., and Tianshili Pharmaceutical Group Co., Ltd. is the holding subsidiary of Tianshili Holding Group Co., Ltd. (hereinafter referred to as "Tianshili Group"), tasly Group is an associate of the Company and the Company has two directors who are also directors of Tasly Group, so Jinhua Pharmaceutical Company is related to Tasly Marketing Group.

(III) The amount of related party transactions in 2014 was 14.6314 million yuan, accounting for 2.13 percent of the amount of similar transactions. The implementation was good and there were no disputes.

Main Contents and Pricing Policy of 3. Related Party Transaction

Jinhua Pharmaceutical Company plans to continue to purchase drugs from Tianshili Marketing Group for sale this year. The main contents of this related party transaction are as follows:

(1) Transaction Target: Compound Danshen Dripping Pills, Yangxue Qingnao Granules, etc.

(2) Transaction Price: Agreement Price.

(3) settlement method: full payment according to the sales amount of last month.

(4) Agreement Validity Period: The validity period of the agreement signed by the above-mentioned related parties is 1 year from the date of signature by the legal representatives or authorized representatives of both parties.

(5) Other matters: If there is a major change in the content of this related party transaction during the implementation of the agreement, the company will disclose it in accordance with relevant regulations, and investors are requested to pay attention.

Purpose of 4. Related Party Transaction and Impact on Listed Companies

This related party transaction is to use Jinhua Pharmaceutical Company's existing sales network in Zhejiang Province to purchase drugs from Tianshili Marketing Group for distribution and sales, thus expanding Jinhua Pharmaceutical Company's business scope, further enhancing the Company's market influence and enhancing the Company's marketing capability. At the same time, Tasly Marketing Group is an indirect holding subsidiary of the Company's associates, and the expansion of its sales channels has increased the scale of corporate sales. The connected transaction will not harm the interests of the Company or the minority shareholders.

hereby announce

Zhejiang Jianfeng Group Co., Ltd.

Board of Directors

April 21, 2015

More information

Chairman Jiang Xiaomeng was named "Fengyun Zhejiang Merchants"

On the evening of January 13, the 2021 "Fengyun Zhejiang Merchants" award ceremony was held in Hangzhou. Ten outstanding Zhejiang businessmen, including Jiang Xiaomeng, chairman of the group company, won the honor. The annual "Fengyun Zhejiang Merchants" selection activity is guided by the Propaganda Department of the Zhejiang Provincial Committee of the Communist Party of China, sponsored by Zhejiang Radio and Television Group, and co-organized by Zhejiang Economic Television, Qianjiang Evening News and Zhejiang Merchants Magazine. Provincial Department of Economics and Information Technology, Provincial Department of Science and Technology, Provincial Department of Commerce, Provincial Federation of Industry and Commerce and many other units jointly co-organized. Since its establishment in 2003, it has been held for 18 sessions, and more than 180 "Fengyun Zhejiang businessmen" have been selected. They are all successful models and fresh samples of Zhejiang's economic development.

2022

01-17

Peak re-listed China's top 100 building materials enterprises

China Building Materials Enterprise Management Association recently released a series of lists of "2021 Top 500 Chinese Building Materials Enterprises", and Jianfeng Group ranked among the "2021 Top 100 Chinese Building Materials Enterprises". This series of lists has been released every year since 2002, and has received extensive attention and active participation from governments at all levels, building materials authorities and building materials companies. It has become a vane of China's building materials industry. Since participating in the selection of the list, the peak has been ranked among the top 100 building materials enterprises in China for many years.

2022

01-04

Hubei "Wisdom and Energy Saving" Focus on Daye Peak

On the morning of December 3, more than 180 people from relevant competent departments at all levels and key energy consuming units in Hubei Province gathered in Daye Jianfeng cement company to visit and understand Daye Jianfeng's practice and experience in intelligent energy conservation. On the same day, the provincial smart energy-saving training meeting organized by the Hubei Provincial Development and Reform Commission was held in daye city. daye peak was the only visiting enterprise arranged for the meeting.

2021

12-13

Daye Peak passed the intellectual property management system certification.

Recently, Daye Jianfeng Cement Company received the intellectual property management system certification certificate issued by Guozhi (Beijing) Certification Company. This is also the first system certificate obtained by the company to implement the intellectual property management standard certification. In recent years, Daye Jianfeng has actively mobilized employees to carry out technological innovation, invention and creation, and timely summarized technological achievements and filed patents. Up to now, it has obtained 31 invention patents and utility model patents. At the same time, Daye's concept of the creation, application, management and protection of intellectual property rights is also increasing, and it continues to increase the promotion of new products and new technologies with high value-added intellectual property rights, and enhance the value of corporate intangible assets. Intensity. The passing of this system certification can not only obtain government incentives and funding, but also the basic conditions for intellectual property work and the prerequisite for applying for related projects.

2021

12-13

The Group Party Committee organized the Sixth Plenary Session of the 19th Central Committee to preach the spirit.

In order to quickly set off an upsurge of studying and implementing the spirit of the Sixth Plenary Session of the 19th Central Committee of the Party, and effectively unify thoughts and actions into the decision-making and deployment of the Party Central Committee with Comrade Xi Jinping as the core, and earnestly learn in the depths, seek new places, and do In practice, on December 1, the party committee of the group company held a spiritual lecture at the Sixth Plenary Session of the 19th Central Committee, which was delivered by Jiang Xiaomeng.

2021

12-13

Group Party Committee to Learn the Spirit of the Sixth Plenary Session of the 19th Central Committee

On the afternoon of November 18, the Party Committee of the Group held a special meeting to learn the spirit of the Sixth Plenary Session of the 19th CPC Central Committee and make arrangements for in-depth study. The Sixth Plenary Session of the 19th Central Committee of the Communist Party of China is an important meeting of overall and historical significance held at the historical intersection of the "two centenary" goals on the occasion of celebrating the centenary of the Communist Party of China. The "Resolution of the Central Committee of the Communist Party of China on the Major Achievements and Historical Experience of the Party's Hundred Years of Struggle" approved by the plenary session is a Marxist programmatic document that inherits the past and the future. It is also an action guide to learn from history, create the future, and realize the great rejuvenation of the Chinese nation. At the special meeting, Jiang Xiaomeng, Secretary of the Party committee of the group, and all the members of the Party committee, from the great achievements, historical significance and historical experience created by the party's 100 year history, since the 18th National Congress of the Communist Party of China, it has adhered to the party's overall leadership, comprehensive and strict governance of the party, economic construction, comprehensive deepening of reform and opening up, political construction, comprehensive rule of law, cultural construction, social construction, ecological civilization construction, national defense and military construction, and maintenance of national security., Adhere to the "one country, two systems" and promote the reunification of the motherland, diplomatic work and other 13 important achievements, comprehensively interpret and study the resolutions of the plenary session.

2021

11-22

< 1...7 8 9...61 > 跳转到页